Corcept Therapeutics (HTD) AI Stock Analysis

0 Followers

Corcept Therapeutics

(BX Swiss:HTD)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Revenue and Earnings GrowthStrong revenue and net-income growth indicate expanding demand and improving operating scale across Corcept’s commercial portfolio. Sustained top-line momentum provides resources to support commercialization and development, while rising earnings strengthen the company’s capacity to fund future growth internally.

Negative Factors

Operating Margin CompressionOperating-margin compression indicates that higher operating costs or other impacts are absorbing part of the benefit from revenue growth. If this persists, it could limit earnings scalability and reduce the cash available for pipeline investment, commercialization, and other capital-allocation priorities.

Corcept Therapeutics Business Overview & Revenue Model

Company Description

Corcept Therapeutics Incorporated, founded in 1998 and headquartered in Menlo Park, California, is a pharmaceutical firm dedicated to the discovery, development, and commercialization of treatments for serious metabolic, oncological, and neuropsychia...

Corcept Therapeutics Earnings Call Summary

Earnings Call Date:Nov 03, 2026(Q3-2026)|Next Earnings Date:Mar 02, 2027

Earnings Call SentimentPositive

The call was strongly positive, with substantial revenue and net-income growth, record endocrinology performance, rapid Lifyorli adoption, positive clinical results and multiple advancing pipeline programs. The company also reiterated its 2026 revenue guidance and highlighted significant future opportunities in Cushing's syndrome, oncology, MASH and ALS. The main negatives were the prior complete response letter for relacorilant, the continuing underdiagnosis of hypercortisolism, the unmet need in platinum-resistant ovarian cancer and limited available information on a potential competing therapy.

Positive Updates

Strong Third-Quarter Financial Performance

Third-quarter 2026 revenue was $340.5 million, increasing 33% from the second quarter and 64% compared with the prior-year period. Net income was $126.8 million, compared with $43 million in Q2 and $19.7 million in the prior-year period.

Negative Updates

Prior Complete Response Letter for Relacorilant

The company originally submitted the relacorilant NDA approximately 20 months before the call and received a complete response letter at the end of the prior year. The FDA subsequently requested a specific global statistical test before the company resubmitted the NDA.

Company Guidance

Corcept reiterated its 2026 revenue guidance of $1.1 billion to $1.2 billion, with the midpoint of the range as its best thinking, and said it expects growth to continue; it expects its current Cushing's syndrome business to generate at least $2 billion in annual revenue by the end of this decade, with the availability of relacorilant driving faster growth to between $3 billion and $5 billion in 2030, while Lifyorli is expected to generate more than $1 billion. The company expects results from its BELLA, TRIDENT and SYNERGY studies by the end of next year, plans to begin a Phase III study in ALS next year, and will soon start a Phase II MASH trial evaluating 100 milligrams of miricorilant daily.

Corcept Therapeutics Risk Analysis

Corcept Therapeutics disclosed 30 risk factors in its most recent earnings report. Corcept Therapeutics reported the most risks in the "Finance & Corporate" category.

Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

2 New Risks

1.Federal legislative and regulatory efforts to implement reference pricing or most-favored-nation pricing models could impact our future product revenues and materially harm our business.Q2, 2026

2.Other companies offer medications to treat patients with platinum-resistant ovarian cancer. The availability of such competing treatments could limit our product revenue.Q2, 2026

Corcept Therapeutics Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

CH:HTD against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
KNSA	80Outperform	$7.52B	66.83	17.27%	―	58.19%	192.34%
LQDA	60Neutral	$4.97B	-56.10	-116.64%	―	798.44%	27.88%
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
SCYX	53Neutral	$33.99M	-2.82	-18.65%	―	543.96%	72.49%
CTOR	44Neutral	$51.60M	-1.09	-102.97%	―	―	―
NSRX	29Underperform	$34.08M	-2.82	-158.83%	―	―	―

* General Sector Average

Performance Comparison

CH:HTD and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
SCYX	SCYNEXIS Inc	3.33	-1.36	-28.94%
KNSA	Kiniksa Pharmaceuticals Ltd. Class A	96.28	55.96	138.79%
LQDA	Liquidia Technologies	58.12	30.08	107.28%
CTOR	Citius Oncology, Inc.	0.52	-0.73	-58.24%
NSRX	Nasus Pharma Ltd.	2.82	-4.59	-61.94%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Corcept Therapeutics AI Stock Analysis